CAPR

Business Context and Reporting Period

Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Capricor is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics, primarily for Duchenne muscular dystrophy (DMD). The company's lead product candidate, Deramiocel, is currently under FDA review with a PDUFA target action date of August 22, 2026. The company has no approved products and generates no product revenue.

Key Financial Metrics

Cash Flow Summary (Q1 2026):
- Operating Activities: $(29.25) million used
- Investing Activities: $(154.64) million used (primarily purchase of marketable securities and property/equipment)
- Financing Activities: $1.47 million provided (stock option exercises)

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $9.5 million (39%) compared to Q1 2025, driven by higher operating expenses.
• R&D Expense Growth: Research and development expenses rose 45% to $27.38 million. This was primarily due to a $5.3 million increase in DMD program costs (manufacturing scale-up and commercial preparation) and a $2.6 million increase in personnel costs.
• G&A Expense Growth: General and administrative expenses increased 55% to $9.40 million, largely driven by a $2.5 million increase in professional services (legal and consulting) related to regulatory and pre-commercial initiatives.
• Liquidity Position: Total cash and marketable securities decreased by approximately $39.5 million from the prior year-end, reflecting operational burn and significant investment in marketable securities and capital assets.
• Investment Income: Investment income increased to $2.90 million from $0.73 million due to higher principal balances in marketable securities.

Guidance, Outlook, Risks, and Unusual Items

• Regulatory Outlook: The FDA has assigned a PDUFA target action date of August 22, 2026, for the Biologics License Application (BLA) for Deramiocel. The company previously received a Complete Response Letter in July 2025 and submitted additional data.
• 2026 Expense Guidance: Management expects to spend approximately $100.0 million to $125.0 million on the Deramiocel program in 2026 (CMC expansion, inventory buildout, clinical/regulatory costs) and $7.0 million to $10.0 million on the exosome platform.
• Material Litigation (Unusual Item): On May 7, 2026 (subsequent to the period end), Capricor filed a lawsuit against Nippon Shinyaku Co., Ltd. (NS) and NS Pharma, Inc. The complaint alleges a fundamental pricing flaw and material breach of the U.S. Distribution Agreement regarding Deramiocel. Capricor seeks rescission of the agreement and the right to distribute the product directly.
• Liquidity Risk: While the company believes current resources are sufficient for at least 12 months, it expects to incur significant losses and may require additional financing for commercialization if Deramiocel is approved.
• Deferred Revenue: $12.0 million remains recorded as deferred revenue from the Japan Distribution Agreement with Nippon Shinyaku, as no performance obligations have been satisfied.

Key Facts for Investor Verification

• Deramiocel Approval Timeline: Verify the status of the FDA review and the likelihood of approval by the August 22, 2026 PDUFA date.
• Litigation Outcome: Monitor the progress of the lawsuit against Nippon Shinyaku, as the outcome determines Capricor's ability to commercialize Deramiocel in the U.S. and potential revenue streams.
• Cash Burn Rate: Assess the sustainability of the current cash position (~$278.6 million) against the projected 2026 operating expenses of $107M-$135M.
• Manufacturing Readiness: Confirm the status of manufacturing scale-up and inventory buildout required for a potential commercial launch.
• European Partnership: Note that the binding term sheet for European distribution with Nippon Shinyaku expired on April 1, 2026, without a definitive agreement.